PMID- 30612138
OWN - NLM
STAT- MEDLINE
DCOM- 20200218
LR  - 20200218
IS  - 1432-0428 (Electronic)
IS  - 0012-186X (Linking)
VI  - 62
IP  - 4
DP  - 2019 Apr
TI  - Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 
      1 diabetes: effects of residual C-peptide.
PG  - 593-597
LID - 10.1007/s00125-018-4804-y [doi]
AB  - AIMS/HYPOTHESIS: Recent studies have demonstrated that residual beta cells may be 
      present in some people with long-standing type 1 diabetes, but little is known 
      about the potential impact of this finding on alpha cell function and incretin 
      levels. This study aimed to evaluate whether insulin microsecretion could 
      modulate glucagon and glucagon-like peptide-1 (GLP-1) responses to a mixed meal 
      tolerance test (MMTT). METHODS: Adults with type 1 diabetes onset after the age 
      of 15 years (n = 29) underwent a liquid MMTT after an overnight fast. Insulin 
      microsecretion was defined when peak C-peptide levels were >30 pmol/l using an 
      ultrasensitive assay. Four individuals with recent-onset type 1 diabetes were 
      included as controls. Glucagon and GLP-1 responses were analysed according to 
      C-peptide patterns. RESULTS: We found comparable peak values, Delta(0-max) levels and 
      AUCs of glucagon and GLP-1 responses in C-peptide-positive participants (n = 9) 
      and C-peptide-negative participants (n = 16) with long-standing diabetes and in 
      participants with recent-onset diabetes (n = 4). Mean glucagon levels, however, 
      differed (p = 0.01). Mean GLP-1 responses were significantly lower according to 
      C-peptide positivity (p < 0.001, ANOVA). Interestingly, GLP-1 levels correlated 
      to glucagon values in C-peptide-positive participants with long-standing diabetes 
      (Pearson's r = 0.915, p = 0.004) and in participants with recent-onset diabetes 
      (p < 0.001) but not in C-peptide-negative participants. 
      CONCLUSIONS/INTERPRETATION: The glucagon response to an MMTT in people with 
      long-standing type 1 diabetes is not reduced by the presence of residual beta 
      cells. The reduction of GLP-1 responses according to residual C-peptide levels 
      suggests specific regulatory pathways.
FAU - Thivolet, Charles
AU  - Thivolet C
AD  - Department of Endocrinology and Diabetes, Lyon-Sud Hospital, Hospices Civils de 
      Lyon, 69310, Pierre-Benite, France. charles.thivolet@chu-lyon.fr.
AD  - UnivLyon, Inserm, INRA, INSA Lyon, Universite Claude Bernard Lyon 1, Oullins, 
      France. charles.thivolet@chu-lyon.fr.
FAU - Marchand, Lucien
AU  - Marchand L
AD  - Department of Endocrinology and Diabetes, Lyon-Sud Hospital, Hospices Civils de 
      Lyon, 69310, Pierre-Benite, France.
AD  - UnivLyon, Inserm, INRA, INSA Lyon, Universite Claude Bernard Lyon 1, Oullins, 
      France.
FAU - Chikh, Karim
AU  - Chikh K
AD  - UnivLyon, Inserm, INRA, INSA Lyon, Universite Claude Bernard Lyon 1, Oullins, 
      France.
AD  - Department of Biochemistry, Lyon-Sud Hospital, Hospices Civils de Lyon, 
      Pierre-Benite, France.
LA  - eng
PT  - Journal Article
DEP - 20190106
PL  - Germany
TA  - Diabetologia
JT  - Diabetologia
JID - 0006777
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Incretins)
RN  - 0 (Insulin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Adult
MH  - Area Under Curve
MH  - Blood Glucose/metabolism
MH  - C-Peptide/*blood
MH  - Diabetes Mellitus, Type 1/*blood/*metabolism
MH  - Female
MH  - Glucagon/*blood
MH  - Glucagon-Like Peptide 1/*blood
MH  - Glucagon-Secreting Cells/metabolism
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Incretins/metabolism
MH  - Insulin/metabolism
MH  - Insulin-Secreting Cells/metabolism
MH  - Male
MH  - Young Adult
OTO - NOTNLM
OT  - Incretins
OT  - Insulin microsecretion
OT  - Pancreatic alpha cells
OT  - Type 1 diabetes
EDAT- 2019/01/07 06:00
MHDA- 2020/02/19 06:00
CRDT- 2019/01/07 06:00
PHST- 2018/10/31 00:00 [received]
PHST- 2018/12/03 00:00 [accepted]
PHST- 2019/01/07 06:00 [pubmed]
PHST- 2020/02/19 06:00 [medline]
PHST- 2019/01/07 06:00 [entrez]
AID - 10.1007/s00125-018-4804-y [pii]
AID - 10.1007/s00125-018-4804-y [doi]
PST - ppublish
SO  - Diabetologia. 2019 Apr;62(4):593-597. doi: 10.1007/s00125-018-4804-y. Epub 2019 
      Jan 6.